Wall Street brokerages expect Fluidigm Co. (NASDAQ:FLDM) to report earnings per share of ($0.11) for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Fluidigm’s earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.11). Fluidigm posted earnings of ($0.06) per share in the same quarter last year, which would suggest a negative year over year growth rate of 83.3%. The business is expected to report its next earnings results on Thursday, February 6th.
On average, analysts expect that Fluidigm will report full-year earnings of ($0.44) per share for the current year, with EPS estimates ranging from ($0.44) to ($0.43). For the next financial year, analysts forecast that the company will report earnings of ($0.36) per share, with EPS estimates ranging from ($0.36) to ($0.35). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Fluidigm.
Fluidigm (NASDAQ:FLDM) last issued its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.19) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.01. The company had revenue of $26.50 million for the quarter, compared to the consensus estimate of $28.74 million. Fluidigm had a negative net margin of 57.10% and a negative return on equity of 25.11%. The firm’s revenue for the quarter was down 8.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.13) earnings per share.
Large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC grew its stake in shares of Fluidigm by 21,055.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,135 shares of the medical research company’s stock worth $29,000 after buying an additional 6,106 shares in the last quarter. Metropolitan Life Insurance Co NY purchased a new position in shares of Fluidigm in the 1st quarter worth $151,000. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Fluidigm in the 2nd quarter worth $154,000. Bailard Inc. purchased a new position in shares of Fluidigm in the 3rd quarter worth $59,000. Finally, Prudential Financial Inc. grew its stake in shares of Fluidigm by 55.6% in the 2nd quarter. Prudential Financial Inc. now owns 15,950 shares of the medical research company’s stock worth $197,000 after buying an additional 5,700 shares in the last quarter. 90.99% of the stock is owned by institutional investors and hedge funds.
Shares of Fluidigm stock opened at $3.46 on Thursday. The company has a market cap of $240.71 million, a price-to-earnings ratio of -4.33 and a beta of 2.21. The company’s 50 day moving average is $2.99 and its 200 day moving average is $5.93. Fluidigm has a twelve month low of $2.12 and a twelve month high of $14.90. The company has a quick ratio of 2.44, a current ratio of 2.89 and a debt-to-equity ratio of 0.33.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
Featured Article: What is a Real Estate Investment Trust (REIT)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.